

## AHI Completes Nasdaq Listing, Secures a US\$12 Million Capital Raise

**Advanced Human Imaging Limited (ASX: AHI) (NASDAQ: AHI) (Advanced Human Imaging or Company)** is pleased to release its Appendix 4C and to provide its shareholders with an update on its activities for the quarter ending December 31, 2021.

### HIGHLIGHTS

- AHI successfully finalises Nasdaq listing and completes a US\$12 million capital raise.
- The potential improvement in liquidity will further accelerate the Company's growth prospects and provide access to critical resources.
- Tinjoy's "The Health Cube" application has launched across multiple Android stores in China, further progress hampered by China's zero-Covid strategy.
- The integration of AHI's *CompleteScan* technology into the Nexus-Vita application is progressing and AHI has already issued a US\$100,000 invoice for work completed to date, which has already been received in full by the Company.
- Cash expenditure increased to \$2,262k in the current quarter. However, after adjusting for once-off items, cash expenditure reduces to \$1,818k, which represents an 12% reduction in spend compared to last year.
- After adjusting for once-off items, net cash used in operating activities reduces from \$1,274k to \$830k for the quarter, which is in line with our expectations.
- The Company received a \$890k R&D rebate during the quarter, the largest in the Company's history.

<b>ASX Code: AHI</b> <b>ABN 85 602 111 115</b>  <b>CORPORATE STRUCTURE</b>  Issued Capital: ~162.5M Options Issued: ~5.8M Perform Rights: ~17.1M Warrants: ~7.1M Share price: \$0.505 (31 Jan '22)	<b>CORPORATE DIRECTORY</b>  <i>Non-Executive Directors</i> <b>Mike Melby</b> <b>Nick Prosser</b> <b>Dato Low Koon Poh</b> <b>Edward F. Greissing Jr</b>  <i>Executive Chairman, CEO</i> <b>Vlado Bosanac</b>  <i>Company Secretary, CFO</i> <b>Steven Richards</b>	<b>CONTACT DETAILS</b>  Unit 5, 71-73 South Perth Esplanade, South Perth, WA 6151  PO Box 190 South Perth, WA 6951  investors@advancedhumanimaging.com www.advancedhumanimaging.com
---	--	--

### **Vlado Bosanac, Chairman and Chief Executive Officer of AHI said:**

"As many investors are no doubt aware, the share price has been under significant pressure over the past few weeks. We certainly understand the concern. However, the share price performance should not take away from the fact that we are now listed on one of the most prominent exchanges in the world, particularly for technology companies. A Nasdaq listing was always going to be the key to us enabling our growth strategy. In a global market characterised by both uncertainty and a certain pandemic, there are many challenges to overcome, not only for AHI but for many other businesses around the globe including but not limited to many of our partners.

We remain focused on executing our plans, to grow awareness and partnerships across the globe. With closing of our Nasdaq initial public offering ("IPO"), we have a strong cash balance that we expect to further bolster

as we near our revenue goals via our near-term partner releases. There are certain challenges which we must face which we will overcome in due course. For example, many of our partners need access to critical skills. Omicron is here whether we like it or not. The harsh reality is that certain projects will simply take us a bit longer to complete in the current climate; importantly, all of our partners remain firmly in place and we are assisting them where possible. The fact of the matter is, our strategic objectives, the quality of our technology and the Company's potential has not changed. We have an incredibly strong foundation from which we will launch this next phase of our growth plans. I am placing additional focus on presenting to global buy side brokers and funds, bringing our company to their attention, with a view to attract larger more cohesive investors to our registry".

### **AHI COMPLETES NASDAQ LISTING**

The Company commenced trading on the Nasdaq on November 19, 2021 under the ticker symbol, (NASDAQ: AHI). The pricing of the Company's U.S. initial public offering of 1,000,000 units was set at a price to the public of US\$10.50 per unit. Each unit issued in the offering consisted of two American Depositary Shares ("ADSs") and one warrant to purchase one ADS. Each ADS offered represents 7 ordinary shares of AHI. The warrants are exercisable immediately and expires three years from the date of issuance and have an exercise price of US\$5.52 per ADS. The ADSs and warrants are immediately separable and were issued separately. Gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately US\$10.5 million.

The Company granted the underwriters a 45-day option to purchase up to an additional 300,000 ADSs and/or up to an additional 150,000 warrants to purchase up to 150,000 ADSs at the public offering price, less underwriting discounts and commissions. In December 2021, the underwriters exercised their option to purchase an additional 300,000 ADSs ("Overallotment") at the public offering price of US\$5.25 per ADS, to conclude a US\$12,072,000 capital raising, including the Overallotment.

### **UPDATE ON PRODUCT LAUNCHES**

On September 14, 2021 the Company announced that Tinjoy had submitted their "The Health Cube" application to multiple Android and Apple app stores. Tinjoy were in the process of implementing their go-to-market strategy, but efforts have been muted by China's "zero-COVID" policy<sup>1</sup> and the resultant restrictions and lockdowns have severely hampered the workforce. Tinjoy's efforts to increase the uptake in new daily active users will simply take a little longer than anticipated, and unfortunately, this is outside of AHI's control.

The integration of AHI's *CompleteScan* technology into the Nexus-Vita application is progressing and AHI has already issued an invoice in the amount US\$100,000 and received payment in full. Although the scope of the project has proven to be more complex than originally anticipated, both parties have committed all available resources to accelerate the development of the application.

As announced to ASX on November 9, 2021, Bearn, a Californian-based wellness technology company, have completed the integration of the AHI software development kit for both the BodyScan and FaceScan and are now preparing their marketplace platform in readiness for application launch. The Company will provide an update to the market as soon as a launch date is confirmed.

The Company announced on December 1, 2021 that it had concluded all definitive agreements with Toronto-based Digital Health provider Cubert Inc who have developed FitTrack My Health ("FitTrack"), a preventative health screening app. Planning is currently underway for the integration of AHI's technology into the FitTrack app.

---

<sup>1</sup> China is one of just a few of countries that have pursued a zero-COVID strategy, which aims to completely eliminate transmission of the virus within the country and allow resumption of normal economic and social activity.

## STRATEGIC INVESTMENTS AND NEXT QUARTER PLANNED ACTIVITY

On April 27, 2021, AHI executed a Binding Heads of Agreement to acquire Physimax Technologies Limited (“Physimax”), an Israeli-based musculoskeletal assessment company. On July 6, 2021, AHI announced that the parties had commenced the process of negotiating a full form acquisition agreement for the acquisition of Physimax, which would see a material reduction in the acquisition amount previously announced by the Company. On December 14, 2021, the Company announced that the parties had mutually agreed to terminate the proposed acquisition, following an extensive due diligence process.

Additionally, AHI announced previously that it had completed due diligence on its partnership and investment in Canadian-based Triage Technologies Inc. (“Triage”), which includes the signing of a binding license agreement and subscription agreement. Under the terms of the license agreement, the companies expect to complete the integration of the Triage application into AHI’s *CompleteScan* platform, with the first demonstratable “DermaScan” product expected to be made available early in 2022. This will be a demonstration product and will only be sold to jurisdictions where the medical approvals have been achieved. The DermaScan component remains a key part of the Company’s *CompleteScan* platform.

AHI’s full suite of products, noting the impact of Triage (“DermaScan”) is well-represented in the graphic below:

### Mobile Device Health Information System

### Empowering Early Intervention With Actionable Data.

Computer Vision and Image Processing technology are already widely used in the healthcare industry. Still, many healthcare services are performed using traditional methods.

Innovation in Computer Vision and Image Processing will reveal new applications which are bound to be disruptive.



**BodyScan**

Identifying risk and the evolution of chronic disease.



**FaceScan**

Using AI and image analysis for more accurate and convenient diagnosis.



**DermaScan**

Enhancing and improving on human error.



**HemaScan**

Reducing the burden on the global healthcare system.



**MKScan**

Injury prevention and rehabilitation through human movement analysis.



Issued Patents



Platforms





## CASHFLOW UPDATE

The Company successfully listed on the Nasdaq Stock Market on November 19, 2021, raising over US\$12 million (including the over-allotment option) as part of its initial public offering. As one might expect, the improvement to the Company's liquidity has made a significant improvement to its net asset and total shareholder equity position. As mentioned above, the Company continues to make progress with the Nexus-Vita and Tinjoy product launches and continues to progress with ongoing development of its *CompleteScan* platform. As previously reported, despite the steady (albeit delayed) advancement, the results are not fully reflected in the table below as the rewards are expected to flow later:

### Cash flow from operations:

Line Item per Published Appendix 4C	Dec '20 QTR \$' 000*	Average of the Previous 4 QTRs \$' 000*	Dec '21 QTR \$ '000*	Change on Dec '20 QTR %	ADJUSTED <sup>1</sup> (Pro forma) Dec'20 QTR \$ '000*	ADJUSTED <sup>1</sup> Change on Dec'20 QTR %
<b>1.1 Cash receipts from customers</b>	456	216	124	<b>73% less</b>	124	<b>73% less</b>
<b>1.2 Operating cash expenditure</b>	(2,071)	(1,794)	(2,262)	<b>9% increase in spend</b>	(1,818)	<b>12% decrease in spend</b>
<b>Net cash from (used in) operating activities</b>	<b>(847)</b>	<b>(1,387)</b>	<b>(1,274)</b>	<b>50% increase in net operating spend</b>	<b>(830)</b>	<b>2% decrease in net operating spend</b>

Table 1. Cash flow summary by quarter. Currency in AUD, unless stated otherwise.

### Cash receipts from Customers:

As Table 1 above suggests, AHI received \$124k from customers during the current quarter. Last year, cash in the amount of \$448k was received from a related party, Body Composition Technologies Pte Ltd ("BCT") for work carried out on partner builds and integrations, as well as license fees owing. The payments received from BCT were once-off in nature and explain the 73% variance in cash receipts from customers compared to this time last year. After adjusting for this once-off item, adjusted (pro forma) cash receipts from customers for last year (December 2020) amounted to \$8k, which means operational cash receipts has increased by \$116k in the current quarter compared to last year, which implies growth of 1450% on last year on an adjusted (pro forma) basis.

<b><sup>1</sup>Adjusted Dec 2020 QTR</b>	<b>QTR \$ '000</b>
Cash receipts from customers – Dec 2020	456
Less: Once-off items	
Cash received from related party as described above	<u>448</u>
Adjusted cash receipts from customers – Dec 2020	8
Cash receipts from customers – Dec 2021	<u>124</u>
<b>Percentage (%) increase in adjusted cash receipts from customers</b>	<b>(Growth in revenue - cash 1450% received from customers)</b>

### Operating cash expenditure:

The operating cash expenditure for the current quarter is \$2,262k, which represents a 9% increase in expenses for the quarter compared to last year. The increase in spend over last year (as well as the previous quarter), is completely offset by the \$890k R&D grant the Company received from the Australian Tax Office (“ATO”) on October 26, 2021, the largest in its history. Additionally, AHI incurred one-off expenses totalling \$444k in the current quarter because of: payments made in relation to the Nasdaq IPO, costs incurred in relation to the setup of the US Office, a one-off marketing payment and additional payroll tax paid on non-cash stock-based compensation, as follows:

<b><sup>1</sup>Adjusted December 2021 QTR</b>	<b>Dec ‘21 QTR \$ ‘000</b>
Operating cash expenditure	2,262
Less: Once-off items	
Additional payroll tax	95
US Office Set	30
Marketing contribution	139
Patent protection	94
Nasdaq IPO expenses	<u>86</u>
	444
Adjusted operating cash expenditure	<u>1,818</u> [\$2,262 - \$444k]
Adjusted net cash used in operating activities	<u>830</u> [\$1,274 - \$444k]

As per the calculation above, when adjusting for once-off and extraordinary items, operating cash expenditure reduces from \$2,262k to \$1,818k. The \$396k increase in expenditure over the previous quarter is completely offset by the \$890k R&D grant received from the ATO, as highlighted by Figure 1. below:

<sup>1</sup>The adjusted December 2021 QTR figures produced in this calculation have been produced for illustrative and commentary purposes only.




Figure 1. Cash receipts and cash payments trendline



### **Cash flow from investing activities:**

During the quarter, AHI made a US\$1 million (AU\$1.4 million) payment to Triage. Under the terms of the Triage Agreement, AHI will invest a total of up to US\$6 million into Triage, being US\$3 million in cash and US\$3 million in equity. The US\$3 million cash investment will be made in instalments over a 14-month period. At the end of the quarter, AHI had made payments to Triage totalling US\$2.5 million.

### **Cash flow from financing activities:**

On November 24, 2021 the Company announced the closing of a US\$10.5m United States IPO on the ASX Platform. In December 2021, the underwriters exercised their option to purchase an additional 300,000 ADSs, equivalent to 2,100,000 Ordinary Shares ("Overallotment"). Gross proceeds from the IPO and Overallotment, before deducting underwriting discounts, commissions and other offering expenses, were US\$12 million. After deducting all related costs, net proceeds for the offering, including the Overallotment, amounted to AU\$14.3 million.

Additionally, 142,600 Warrants (represented by 998,200 Ordinary Shares) were exercised at an exercise price of US\$5.52 per Warrant and as a result, US\$787k (A\$1.1 million) in option proceeds were received by Company during the quarter.

The repayment of borrowings relates to the short-term funding of the Company's directors' and officers' insurance program ("D&O Insurance") to make best use of its available cash flow resources. As is typically the case, with the Company now dual listed across two major exchanges, this has resulted in a large increase in D&O Insurance costs.

### **Use of funds:**

The Company had AU\$12.2 million cash at bank at the end of the quarter. And as highlighted above, during the quarter AHI made payments in the amount of AU\$1.4 million in relation to its investments in Triage. The investment in Triage relates to the development of AHI's *CompleteScan* Platform, as summarised in the table below:

ENTITY	COMPLETESCAN COMPONENT	SHORT DESCRIPTION
Triage	DermaScan	Skin disease detection for over 500 skin conditions.

### **Steven Richards, Chief Financial Officer of Advanced Human Imaging said:**

"Undoubtedly, it has been a most productive quarter. We have successfully listed on Nasdaq and during the process we raised over US\$12 million. Operationally, we are making good inroads in relation to the development of the *CompleteScan* Platform. We continue to give our Partners as much support as we can, and we remain focused on collaborating with them to maximise revenue opportunities.

Moving forward, with the global economy under pressure, including the availability and supply of critical resources, we must simply rise to the challenge as we did with the Nasdaq listing. We always said that we were going to list on Nasdaq, and that is exactly what we ended up doing. With a healthy cash at bank balance of AU\$12 million, we certainly have the means to overcome these challenges and progress our growth ambitions with a high degree of confidence."

## **RELATED PARTY TRANSACTIONS**

During the quarter, AHI made the following payments under Item 1 of the attached Appendix 4C:

Director's fees, under a contract for services:	(\$ 9k)
Legal fees paid to Steinepreis Paganin:	(\$43k)
Total related party payments under Item 1:	(\$52k)

The following payments made under Item 2 of the attached Appendix 4C:

Funds advanced to joint venture partner, BCT:	(\$100k)
Funds advanced to US subsidiary, MyFiziq, Inc.:	(\$110k)
Total related party payments under Item 2:	(\$210k)

## **Forward-Looking Statements:**

This document may include forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning Advanced Human Imaging Limited's planned partner integrations, forecast partner revenue, and other statements that are not historical facts. When used in this document, the words such as "could", "plan", "estimate", "expect", "intend", "may", "potential", "should", and similar expressions are forward-looking statements. Although Advanced Human Imaging Limited believes that its expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements.

## **About Advanced Human Imaging:**

AHI has developed and patented a proprietary technology which enables its users to privately check, track, and accurately assess their dimensions, solely using a smartphone. AHI refers to this physical measurement and analysis tool as "BodyScan". AHI is globalizing its technology to assist individuals, communities and populations live healthier lives, worldwide.

AHI's patented technology allows individuals, via an automated system, take a series of images of themselves using a smartphone which delivers accurate and repeatable measurements across the individual's entire body. These measurements allow the individual to understand his/her dimensions and the physical changes which they are undergoing through diet, exercise, and lifestyle. Further, the images that AHI captures also provide the individual with an understanding of their health risk related to certain chronic diseases (including obesity and related diseases such as diabetes). AHI uses global standards set by the World Health Organization, and the International Diabetes Federation when assessing and deriving this information feedback loop.

AHI has recently advanced its technology to run these complex mathematical algorithms directly on the user's smartphone, rather than limiting that computation to the Cloud. AHI's overarching technology strategy has been to take advantage of the mobile device's accelerated performance, specifically by utilizing on-device general purpose Graphic Processing Units ("GPU").

AHI delivers a non-invasive, highly accurate and privacy-sensitive solution which returns results within seconds. AHI leverages machine-learning and computer vision to analyse images, detect pose and joint features, and create non-personally identified data for measurement estimation. AHI takes advantage of dedicated GPU libraries such as TensorFlow Lite (Android) and Metal (Apple) to run prediction models, which have been trained with a substantial and diverse human data set proprietary to the company from around the globe, which is enabled on device to process multiple captured images in fractions of a second. The result is a solution that runs on-device and does not sacrifice speed, security, or privacy. Images and private information never leave the users personal device, ensuring security and privacy standards are met across global regions and requirements. This unrivalled process allows us to produce exceptional results and simplify the output of useful, reliable, digital measurements and remove the human error otherwise present in traditional methods.

AHI's MultiScan platform simplifies the collection of bio metric measurements across the body, vital signs, and skin conditions, reducing the human error present in traditional information gathering and analysis methods.

---

For more information please visit: [www.advancedhumanimaging.com](http://www.advancedhumanimaging.com)

**For more information contact:**

**Vlado Bosanac,**  
Chief Executive Officer  
**Advanced Human Imaging Limited**  
E: [investors@advancedhumanimaging.com](mailto:investors@advancedhumanimaging.com)

**Steven Richards,**  
Chief Financial Officer  
**Advanced Human Imaging Limited**  
E: [investors@advancedhumanimaging.com](mailto:investors@advancedhumanimaging.com)



## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Advanced Human Imaging Limited

**ABN**

85 602 111 115

**Quarter ended ("current quarter")**

31 December 2021

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>			
1.1 Receipts from customers		124	232
1.2 Payments for			
(a) research and development		-	-
(b) product manufacturing and operating costs		-	-
(c) advertising and marketing		(168)	(180)
(d) leased assets		-	-
(e) staff costs		(1,154)	(2,131)
(f) administration and corporate costs		(940)	(1,736)
1.3 Dividends received (see note 3)		-	-
1.4 Interest received		-	-
1.5 Interest and other costs of finance paid		(26)	(35)
1.6 Income taxes paid		-	-
1.7 Government grants and tax incentives		890	890
1.8 Other (provide details if material)			
<b>1.9 Net cash from / (used in) operating activities</b>		<b>(1,274)</b>	<b>(2,960)</b>
<b>2. Cash flows from investing activities</b>			
2.1 Payments to acquire or for:			
(a) entities		(1,396)	(2,077)
(b) businesses		-	-
(c) property, plant and equipment		(54)	(90)
(d) investments		-	-
(e) intellectual property		-	(16)
(f) other non-current assets		-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	(210)	(401)
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(1,660)</b>	<b>(2,584)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	14,336	14,336
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	1,100	1,100
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	700
3.6	Repayment of borrowings	(662)	(687)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Call Option Control Account)	-	75
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>14,774</b>	<b>15,524</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	369	2,229
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,274)	(2,960)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1,660)	(2,584)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	14,774	15,524
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	<b>Cash and cash equivalents at end of period</b>	<b>12,209</b>	<b>12,209</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	12,209	369
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>12,209</b>	<b>369</b>

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(52)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	(210)
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

<b>7.</b>	<b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other - Convertible note: Asia Cornerstone Asset Management	-	-
7.4	<b>Total financing facilities</b>	-	-
7.5	<b>Unused financing facilities available at quarter end</b>		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.  -		

<b>8.</b>	<b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,274)
8.2	Cash and cash equivalents at quarter end (item 4.6)	12,209
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	12,209
8.5	<b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	9.58
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?  Answer: N/a	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?  Answer: N/a	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?  Answer: N/a	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

## **Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: .....31 January 2022.....

Authorised by: .....By Order of the Board.....  
(Name of body or officer authorising release – see note 4)

## **Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.